Skip to main content
. 2023 Jan 6;13:1088732. doi: 10.3389/fphar.2022.1088732

FIGURE 10.

FIGURE 10

Sunitinib can decrease KCNJ3 expression and enhance apoptosis in U20S osteosarcoma cells. (A) Evaluation of U20S osteosarcoma cell viability using CCK-8 assay after exposure to various concentrations of sunitinib for 24 h. (B,C) The expression level of KCNJ3 protein of osteosarcoma cells in control and sunitinib treatment groups. (D,E) The protein expression levels of Bax, Bcl-2, and caspase3 in osteosarcoma cells in the sham (0μM) and sunitinib treatment groups. (F,G) TUNEL staining was used to detect osteosarcoma cell apoptosis after sunitinib treatment (bar: 50 μm; nuclei: blue; positive cells: green). All experiments were repeated in triplicates (n = 3). The obtained data are represented as mean ± SE. Significance: @ p-value < .05, @@ p-value < .01, @@@ p-value < .001, vs. sham (0 μM) group. # p-value < .05, ## p-value < .01, ### p-value < .001.